al fabricated CD19 CAR‐Ts from UCB and subsequently evaluated the oncolytic potential preclinically in the context of diffuse large B cell lymphoma (DLBCL).[68]. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.